Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: Yesterday, Today, and Tomorrow

Appelbaum, Frederick R.

doi:10.1200/jco.2007.15.7479

Cited by 20 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This therapeutic option should be considered early during the course of the disease and integrated into the long-term concept of lymphoma therapy [1,22,23] PFS rates according to disease status at AHCT were 90% in CR, 63% in primary refractory and 50.9% in relapsed disease. In particular, patients with HL who received BuEM had decreased relapse risk compared to those with NHL.…”

Section: Discussionmentioning

confidence: 98%

Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas

Sakellari

Mallouri

Batsis

et al. 2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

Optimal conditioning remains a challenge in lymphomas. We designed a regimen consisting of Busulfex, etoposide and melphalan (BuEM). We retrospectively analyzed the outcome of patients conditioned with carmustine, etoposide, cytarabine and melphalan (BEAM) or BuEM in matched-pair analysis on a planned 2:1 ratio. Eighty-seven patients treated with BEAM who fulfilled the matching criteria were randomly selected. Two-year progression-free survival/overall survival (PFS/OS) were 63.2%/76.7% for BEAM vs. 65.6%/79.8% for BuEM after 64.7 and 42.7 months, respectively. Furthermore, marginally better PFS and OS were noted in Hodgkin lymphoma (HL) after BuEM. In multivariate analysis, PFS was superior in HL, chemosensitive disease and complete remission post-transplant. BEAM correlated with faster engraftment, reduced infections, less mucositis and liver toxicity, and BuEM with less need for blood cell and platelet transfusions and granulocyte colony-stimulating factor administration. In conclusion, BuEM was well tolerated and equally highly efficacious as BEAM for non-Hodgkin lymphoma and offered marginally significantly improved PFS and OS in HL with acceptable toxicity and zero mortality.

show abstract

Section: Discussionmentioning

confidence: 98%

Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas

Sakellari

Mallouri

Batsis

et al. 2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…In general, the standard care is high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients who are sensitive to salvage chemotherapy. There are no standard options of treatment for patients who show no response to second-line regimens, nor for patients who are not eligible for transplants [1,2]. For those patients it is therefore very important to establish the satisfactory salvage therapy with optimal response and a low toxicity rate.…”

mentioning

confidence: 99%

Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience

Rybka¹,

Jurczak²,

Giza³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. The treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains challenging. Gemcitabine is a cytidine analog with a wide spectrum of antitumor activity. Gemcitabine treatment is widely used to treat patients with certain solid tumors and relapsed/refractory hematological malignancies. There are several reports indicating that this compound is active in lymphoid malignancies. In patients with relapsed or refractory HL and NHL, gemcitabine has demonstrated efficacy as a single agent and in combination with other cytostatics. Objectives. The aim of the study was to analyze the efficacy and toxicity of gemcitabine-based chemotherapy in patients with relapsed or refractory lymphomas. Material and Methods. The study evaluated 68 heavily pretreated patients with relapsed/refractory HL and NHL. The median age of the patients was 36 years. All the patients received gemcitabine-based chemotherapy (gemcitabine monotherapy or gemcitabine in combination with other cytostatics). Results. The overall response rate was 46%. Complete response was achieved by 21% of the patients and partial response by 25%. Out of those who responded to gemcitabine treatment, 26 patients proceeded to autologous stem cell transplant. Toxicities connected with gemcitabine therapy occurred in 44% of the patients and included grade 3/4 neutropenia, thrombocytopenia and anemia. Conclusions. The results suggest that gemcitabine-based salvage chemotherapy is effective and well tolerated in patients with relapsed/refractory HL and NHL (Adv Clin Exp Med 2015, 24, 5, 783-789).

show abstract

“…6 Toxicity of this chemotherapy is acceptable and definitely lower than that observed with the standard BEAM or LACE regime. But the incidence of MDR bacterial infections is very high in India and urgent measures are needed to address this issue.…”

Section: Resultsmentioning

confidence: 88%

Untitled

2017

HTIJ

View full text Add to dashboard Cite

Autologous Stem Cell Transplantation (ASCT) is the main stay of care in relapsed lymphomas including diffuse large B-cell lymphoma (DLBCL). There are different conditioning regimens which differ in efficacy and toxicity. Carmustine, etoposide, ARA-C, melphalan (BEAM), lomustine, etoposide, ARA-C, melphalan (LEAM) and lomustine, ARA-C, cyclophosphamide, etoposide (LACE) are commonly used condition in regimes. Therefore a less toxic regimen might improve the results in relapsed lymphoma patients.

show abstract

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: Yesterday, Today, and Tomorrow

Cited by 20 publications

References 26 publications

Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas

Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas

Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience

Untitled

Contact Info

Product

Resources

About